Novartis AG NVSEF
Annual
Quarterly
No annual revenue total was found in Novartis AG's SEC filings.
Novartis AG (NVS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was $17.6 billion. As of Dec 31, 2025 it held $11.4 billion in cash and investments and $31.3 billion in total debt.
Revenue
—
Net income
$13.97B
+17.0% vs prior year
Operating cash flow
$19.14B
+8.7% vs prior year
Free cash flow
$17.60B
+8.3% vs prior year
EPS
$7.15
+21.8% vs prior year
Dividend per share
None
Shares outstanding
1.91B
-3.4% vs prior year
Net cash
$-19.90B
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NVS (NYSE), NVSEF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Basel, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1114448
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | $17.6B | $14.5B | $9.8B | $7.9B | $10.1B |
| Net income | $14.0B | $11.9B | $14.9B | $7.0B | $24.0B |
| Diluted EPS | $7.15 | $5.87 | $7.10 | $3.17 | $10.63 |
| Operating cash flow | $19.1B | $17.6B | $14.5B | $14.2B | $15.1B |
| Free cash flow | $17.6B | $16.3B | $13.4B | $13.3B | $14.0B |
| Total assets | $110.9B | $102.2B | $99.9B | $117.5B | $131.8B |
| Total liabilities | $64.4B | $58.1B | $53.2B | $58.0B | $64.0B |
| Stockholders' equity | $46.5B | $44.1B | $46.8B | $59.4B | $67.8B |
| Cash and investments | $11.4B | $11.5B | $13.4B | $7.5B | $12.4B |
| Total debt | $31.3B | $27.2B | $23.1B | $25.1B | $28.3B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
| 6-K | Current report (foreign issuer) | Sep 1, 2026 | Sep 1, 2026 |
| 6-K | Current report (foreign issuer) | Jul 21, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jun 11, 2026 | Jun 11, 2026 |
All 1000 Novartis AG SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.